Quantification of N-Nitroso Varenicline in Varenicline Tartrate by LC/MS-QTOF

Importance of the Topic

Varenicline tartrate is an effective smoking cessation agent whose secondary amine moiety can form N-nitroso varenicline, a genotoxic impurity, when trace nitrites are present during manufacture. Sensitive and accurate quantification of this impurity is critical to ensure patient safety and meet regulatory standards.

Objectives and Study Overview

This study presents a quantitative method for determining N-nitroso varenicline in both the active pharmaceutical ingredient (API) and finished tablet form of varenicline tartrate. The goal was to leverage the Shimadzu LCMS-9050 UHPLC-QTOF system to achieve high sensitivity, accuracy, and compliance with regulatory limits.

Methodology and Instrumentation

Chromatographic and mass spectrometric parameters as well as sample preparation steps are summarized below:

• Chromatography: Nexera X3 UHPLC with Shim-pack Velox C18 column (100 mm × 2.1 mm, 1.8 µm) at 35 °C; mobile phase A: 0.1 % formic acid in water, B: 0.1 % formic acid in methanol; gradient from 20 % to 80 % B over 6 min, 100 % B at 10–11 min, return to 20 % B by 15 min; flow rate 0.30 mL/min; injection volume 5 µL.
• Mass Spectrometry: LCMS-9050 QTOF in positive ESI mode; ion accumulation technology enabled for ~30× sensitivity enhancement; nebulizing gas 2 L/min, drying gas 5 L/min, heating gas 15 L/min; interface 400 °C, DL 300 °C, heat block 200 °C; MRM transition m/z 241.1084 → 211.1105.
• Sample Preparation: API samples (48 mg) dissolved in methanol (50 mL), vortexed and filtered. Tablet samples ground, dissolved to 0.5 mg/mL in methanol, sonicated for 40 min, centrifuged at 4500 rpm for 15 min, then filtered.

Results and Discussion

• Ion accumulation mode increased the signal of N-nitroso varenicline by approximately 30-fold compared to conventional acquisition, enabling ultratrace detection.
• Calibration curve demonstrated excellent linearity over 0.1–50 ng/mL (R² = 0.9994) with point-by-point accuracy between 94.4 % and 104.0 %.
• Reproducibility studies (n=6) at 1, 5 and 20 ng/mL yielded RSD values below 3.5 % for retention time and peak area.
• Recovery experiments in both API and tablet matrices showed 95.86 %–106.65 % recoveries with RSD ≤2.2 %, confirming method reliability.

Benefits and Practical Applications

The described UHPLC-QTOF method offers high mass accuracy and sensitivity, surpassing regulatory requirements by over 100-fold. Its compatibility with standard UHPLC systems and robust ion accumulation makes it well suited for routine pharmaceutical quality control and safety assessment.

Future Trends and Opportunities

Advancements may include further refinement of ion accumulation parameters, adaptation to other nitrosamine impurities, integration with automated data analysis workflows, and deployment on next-generation high-resolution MS platforms to enhance throughput and dynamic range.

Conclusion

The Shimadzu LCMS-9050 UHPLC-QTOF method provides a sensitive, accurate, and reproducible solution for quantifying N-nitroso varenicline in varenicline tartrate. Its performance meets stringent regulatory criteria and supports comprehensive quality assurance in pharmaceutical analytics.

Reference

Huiyu Wang. Quantification of N-Nitroso Varenicline in Varenicline Tartrate by LC/MS-QTOF, Shimadzu Application Note, First Edition: Jun. 2025.